 This is a multicentre, open-label, randomized controlled trial in 152 patients with recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: a a 12-week course of treatment with Forxiga, metformin, insulin glargine and lifestyle therapy, and b standard diabetes therapy, and followed for a total of 64 weeks 1 year and 3 months. In all participants with HbA1C7.3 at the 12 week visit, glucose-lowering medications will be discontinued and participants will be encouraged to continue with lifestyle modifications and regular glucose monitoring. Participants with HbA1C 7.3 at this visit or who experience hyperglycemia relapse after stopping drugs will receive standard glycemic management as informed by the current Canadian Diabetes Association clinical practice guidelines. 